Showing 2541-2550 of 5693 results for "".
- Focus Vision Supplements Now Offer Eyelid Products to Soothe Dry Eye and Aid in Postoperative Healinghttps://modernod.com/news/focus-vision-supplements-now-offer-eyelid-products-to-soothe-dry-eye-and-aid-in-postoperative-healing/2478622/Covalent Medical, owner of Focus Vision Supplements, has developed two new products to aid in pre/postoperative care and soothe the symptoms of occasional dry eye and blepharitis. Focus Eyelid Scrub Formula is a preservative-free, deep-cleaning foam eyelid cleanser
- TearClear Announces Successful Completion of Pre-IND Meeting With the FDA for a Preservative-Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucomahttps://modernod.com/news/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma/2478608/TearClear announced successful completion of pre-IND (investigational new drug) meeting with the FDA regarding the development plan for the preservative-free multi-dose delivery of a proprietary latanoprost formulation, including the clinical study design for the registration
- When Coronavirus Vaccines Are Ready, Dentists, Optometrists May Give Shotshttps://modernod.com/news/when-coronavirus-vaccines-are-ready-dentists-optometrists-may-give-shots/2478599/With multiple COVID-19 vaccines rapidly heading toward approval, optometrists and dentists are pushing for the authority to immunize patients during routine eye exams and dental cleanings. These medical professionals say their help will be needed to distribute the vaccines
- Doctors Report Patients’ Health Declining Due to Delayed or Inaccessible Care During COVID-19 Pandemichttps://modernod.com/news/doctors-report-patients-health-declining-due-to-delayed-or-inaccessible-care-during-covid-19-pandemic/2478581/Patients’ overall health continues to suffer due to the pandemic, with the majority of primary care physicians reporting that their patients’ mental health has declined during the past 8 months, according to a FierceHealthcare
- EyePoint Pharmaceuticals Presents Positive Data of Yutiq and Dexycu in Four Poster Sessions at AAO 2020https://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-sessions-at-aao-2020/2478559/EyePoint Pharmaceuticals announced that positive data for Yutiq and Dexycu were featured in four presentations at the recent American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Data presented included: Statistically significant effi
- Stoke Therapeutics Nominates Next Preclinical Target in Genetic Eye Diseasehttps://modernod.com/news/stoke-therapeutics-nominates-next-preclinical-target-in-genetic-eye-disease/2478539/Stoke Therapeutics announced the nomination of OPA1 as its second preclinical candidate. “Based on new preclinical data, we are announcing today the expansion of our pipeline with the nomination of OPA1 as our next preclinical target,” Edward M. Kaye, MD, Chief Executive Offi
- Adaptilens Announces $1.6 Million in Seed Funding for Development of Accommodating IOLhttps://modernod.com/news/adaptilens-announces-1-6-million-in-seed-funding-for-development-of-accommodating-iol/2478536/Adaptilens announced a $1.6 million seed funding to fund the company’s development of an innovative accommodating IOL with the aim of allowing patients to live their lives free of glasses and contact lenses. The funding was led by Pillar VC with additional participat
- CDC Now Says Wearing a Mask Protects the Wearer, Toohttps://modernod.com/news/cdc-now-says-wearing-a-mask-protects-the-wearer-too/2478538/For months it has been clear that wearing a face mask reduces the transmission of COVID-19, because it prevents your respiratory droplets from spreading and potentially infecting other people. Now the Centers for Disease Control has highlighted another benefit of mask-wearing that many hoped or s
- Hoya Surgical Optics Introduces On-Demand Platform Qube Pro Powered by Eyeflexahttps://modernod.com/news/hoya-surgical-optics-introduces-on-demand-platform-qube-pro-powered-by-eyeflexa/2478514/Hoya Surgical Optics obtained CE Mark for “Qube pro powered by eyeflexa,” a technology that can support both cataract and vitreoretinal surgery. Eyeflexa is a multi-upgrade platform designed to evolve with the changing needs of ophthalmic surgeons, according to a company news r
- Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement for Dextenza and OTX-TIC in Asiahttps://modernod.com/news/ocular-therapeutix-and-affamed-therapeutics-announce-license-agreement-and-collaboration-for-dextenza-and-otx-tic-in-asia/2478479/Ocular Therapeutix announced a license agreement and a collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC in Greater China, South Korea, and the ASEAN markets. Dextenza is currently approved in the U.S. for the treatment of post-surgical ocul